Journey Medical (DERM) Expected to Post Earnings on Tuesday

Journey Medical (NASDAQ:DERM) is expected to announce its Q2 2026 results after the market closes on Tuesday, August 11th. Analysts expect Journey Medical to announce earnings of ($0.01) per share and revenue of $18.3590 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Tuesday, August 11, 2026 at 4:30 PM ET.

Journey Medical (NASDAQ:DERM) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.01). The company had revenue of $15.96 million during the quarter, compared to the consensus estimate of $15.47 million. Journey Medical had a negative net margin of 14.82% and a negative return on equity of 35.57%. On average, analysts expect Journey Medical to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Journey Medical Price Performance

Shares of NASDAQ DERM traded up $0.07 during trading on Tuesday, hitting $6.54. The company had a trading volume of 84,790 shares, compared to its average volume of 220,949. Journey Medical has a 52 week low of $4.31 and a 52 week high of $9.56. The business’s 50-day moving average is $6.54 and its 200 day moving average is $6.72. The company has a market cap of $180.05 million, a P/E ratio of -17.66 and a beta of 1.08. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.47 and a current ratio of 1.72.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the company. Wall Street Zen upgraded Journey Medical from a “hold” rating to a “buy” rating in a report on Saturday, June 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Journey Medical in a report on Friday, July 17th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Journey Medical currently has an average rating of “Hold” and an average price target of $13.00.

Institutional Trading of Journey Medical

Several hedge funds and other institutional investors have recently modified their holdings of DERM. Occudo Quantitative Strategies LP grew its holdings in shares of Journey Medical by 22.3% during the fourth quarter. Occudo Quantitative Strategies LP now owns 18,913 shares of the company’s stock valued at $146,000 after buying an additional 3,443 shares in the last quarter. Opaleye Management Inc. lifted its stake in Journey Medical by 0.4% in the 4th quarter. Opaleye Management Inc. now owns 975,000 shares of the company’s stock worth $7,517,000 after acquiring an additional 3,936 shares in the last quarter. Bank of America Corp DE lifted its stake in Journey Medical by 4,707.0% in the 2nd quarter. Bank of America Corp DE now owns 4,134 shares of the company’s stock worth $30,000 after acquiring an additional 4,048 shares in the last quarter. Barclays PLC boosted its position in Journey Medical by 28.2% during the 4th quarter. Barclays PLC now owns 22,521 shares of the company’s stock worth $174,000 after acquiring an additional 4,955 shares during the period. Finally, Raymond James Financial Inc. purchased a new position in Journey Medical during the 2nd quarter valued at about $36,000. Institutional investors and hedge funds own 7.25% of the company’s stock.

Journey Medical Company Profile

Journey Medical Corp, headquartered in Fairfield, New Jersey, is a commercial dermatology company focused on acquiring, developing and marketing prescription dermatology products in the United States. Since its incorporation in 2019, the company has built a portfolio of both branded and generic topical therapies designed to address a range of skin conditions, including acne, atopic dermatitis, fungal infections and inflammatory lesions.

The company’s product lineup features antibiotic/anti-inflammatory combinations and corticosteroid-based formulations delivered through proprietary gel, cream and foam vehicles.